SCHEMBL743346

SCHEMBL743346

O=C(Nc1n[nH]c2sc(C(=O)NC3(c4ccccc4)CCCC3)cc12)c1cccs1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 1/20 0.39
DYRK1A Q13627 1/20 0.39
SMN1; SMN2 Q16637 6/20 0.38
MAPK1 P28482 2/20 0.38
MAPT P10636 7/20 0.37
RAB9A P51151 6/20 0.37
NPC1 O15118 5/20 0.37
LMNA P02545 4/20 0.37
NFKB1 P19838 2/20 0.37
NFKB2 Q00653 2/20 0.37
RELA Q04206 2/20 0.37
KMT2A Q03164 5/20 0.36
MEN1 O00255 4/20 0.36
HPGD P15428 3/20 0.36
ALDH1A1 P00352 3/20 0.36
HSD17B10 Q99714 2/20 0.36
POLB P06746 1/20 0.36
KCNK3 O14649 1/20 0.36
KCNK9 Q9NPC2 1/20 0.36
CCNA2 P20248 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL741880 0.96 DYRK1A (0.42) DYRK1ASMN1; SMN2MAPK1MAPTRAB9A
SCHEMBL741273 0.84 HSD17B13 (0.40) TACR3DYRK1ASMN1; SMN2MAPTRAB9A
SCHEMBL4632698 0.81 SMN1; SMN2 (0.49) SMN1; SMN2MAPK1MAPTRAB9ANPC1
SCHEMBL742455 0.81 AURKA (0.55)
SCHEMBL741934 0.80 HSD17B13 (0.42) DYRK1ASMN1; SMN2MAPTRAB9ANPC1
SCHEMBL742870 0.80 MAPK1 (0.43) DYRK1ASMN1; SMN2MAPK1MAPTRAB9A
SCHEMBL741485 0.80 AURKA (0.52)
SCHEMBL4092150 0.79 SMN1; SMN2 (0.40) TACR3DYRK1ASMN1; SMN2MAPK1MAPT
SCHEMBL742286 0.78 DYRK1A (0.38) DYRK1ASMN1; SMN2MAPK1RAB9ANPC1
SCHEMBL739839 0.78 HDAC6 (0.44) SMN1; SMN2MAPTRAB9ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US claimed
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US disclosed